Illumina Inc. (ILMN) has a MarketKingdoms composite score of 71.0 (B+), an B-range rating. It ranks 243rd of 1,866 covered companies, 9th of 78 in Healthcare (sector average 64.5) and 1st of 13 in Diagnostics & Research. Scores as of 2026-10-25.
Its strongest lenses are Industry opportunity at 90 (Healthcare average 81) and KPI momentum at 87 (Healthcare average 78). Its weakest lenses are Price (valuation) at 14 (sector average 50) and Expansion (growth) at 46 (sector average 50).
| Lens | Type | ILMN | Healthcare average | Diagnostics & Research average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 90 | 81 | 90 | 95th |
| Stock selection | Research signal | 84 | 79 | 83 | 78th |
| KPI momentum | Research signal | 87 | 78 | 85 | 78th |
| Catalyst watch | Research signal | 80 | 74 | 77 | 91st |
| Price (valuation) | Fundamental lens | 14 | 50 | 32 | 6th |
| Expansion (growth) | Fundamental lens | 46 | 50 | 52 | 46th |
| Quality (profitability) | Fundamental lens | 66 | 50 | 42 | 72nd |
| Trend (momentum) | Fundamental lens | 86 | 50 | 69 | 96th |
The most recent call analysed was held on 2026-07-30 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is +22.1%: its price is well above the path its market, sector and industry moves explain (the model reads it as strongly overvalued versus that path). Factor sensitivity: market beta 1.65, sector beta -0.63, industry beta 2.03; the factor model explains 49% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | 69.4 | B | -4.1% |
| Agilent Technologies Inc. (A) | 69.2 | B | -3.1% |
| Revvity Inc. (RVTY) | 69.2 | B | +8.2% |
| IQVIA Holdings Inc. (IQV) | 68.8 | B | -16.5% |
| Labcorp Holdings Inc. (LH) | 68.8 | B | -13.5% |
| Natera Inc. (NTRA) | 68.5 | B | -22.9% |
| Charles River Laboratories International Inc. (CRL) | 68.0 | B | -15.8% |
| Waters Corp. (WAT) | 67.9 | B | -6.2% |
Illumina Inc. financial statements · Healthcare sector ranking · Diagnostics & Research industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.